Bodil Willumsen

Title: Bodil Willumsen: Innovator in Antibody-Drug Conjugates

Introduction

Bodil Willumsen is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). Her innovative work focuses on improving the formulation and efficacy of these therapeutic agents.

Latest Patents

Bodil Willumsen holds a patent for "Lyophilized anti-tissue factor antibody-drug conjugates." This patent discloses surfactant-free lyophilized formulations of ADCs, specifically targeting anti-tissue factor ADCs. The formulations are designed to be particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drugs. The excipients used in these formulations include histidine, sucrose, trehalose, mannitol, and glycine.

Career Highlights

Bodil is currently associated with Genmab A/S, a leading biotechnology company specializing in the development of innovative antibody therapies. Her work at Genmab has been instrumental in advancing the field of ADCs, contributing to the development of new treatments for various diseases.

Collaborations

Bodil collaborates with talented professionals in her field, including Jesper Valbjørn and Xiaona Jing. These collaborations enhance the research and development efforts at Genmab, fostering innovation and progress in biopharmaceuticals.

Conclusion

Bodil Willumsen's contributions to the field of antibody-drug conjugates exemplify her commitment to advancing medical science. Her innovative formulations and collaborative efforts continue to pave the way for new therapeutic options.